Please provide your email address to receive an email when new articles are posted on . The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative ...
At week 24, no significant difference in PASDAS was observed between the golimumab and methotrexate group and the placebo and methotrexate group. More participants in the placebo and methotrexate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results